UK calls for access to new AMD therapies

Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.

Related Content:

Retina

Recent Treatment Advances in Retinal Disease

Application for Genentech’s faricimab accepted by U.S. FDA for treatment of wet AMD and DMO

Drug Delivery Methods Explored for Retinal Disease